JP Morgan Chase’s LAVA Therapeutics LVTX Stock Holding History

JP Morgan Chase’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,300	Closed	-$1.65K	–	7418
2025 Q1	$1.65K	Buy	+1,300	New	+$1.45K	﹤0.01%	6572

Other funds holding LVTX

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

PFA

Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase's LVTX Position: Q2 2025 in Review

JP Morgan Chase sold out of LAVA Therapeutics (LVTX) in Q2 2025, closing a stake of 1,300 shares — an estimated $1.65K sold.

JP Morgan Chase first reported a position in LVTX in Q1 2025 and held it in 1 quarter. The position peaked at $1.65K in Q1 2025. 19 funds tracked by Wall St. Rank hold LVTX as of Q2 2025.

JP Morgan Chase reported no remaining LAVA Therapeutics position as of Q2 2025 after selling out during the quarter.
JP Morgan Chase sold 1,300 LAVA Therapeutics shares in Q2 2025, an estimated $1.65K.
JP Morgan Chase first reported a position in LAVA Therapeutics in Q1 2025 and held it in 1 quarter.
JP Morgan Chase's LAVA Therapeutics position peaked at $1.65K in Q1 2025.
19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.